1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Mettler-Toledo reported second-quarter 2025 reported sales of $983.2 million, up 4% from a year earlier, and adjusted EPS of $10.09, up 5%. GAAP diluted EPS fell to $9.76 from $10.37, which included a one-time non-cash tax benefit in the prior-year period. The company raised its full-year 2025 adjusted EPS forecast to $42.10 to $42.60 from $41.25 to $42.00, while local currency sales growth guidance of 1% to 2% was unchanged.
Q2 2025 reported sales rose 4% to $983.2 million; local currency sales rose 2%.
Q2 diluted EPS was $9.76 vs. $10.37 a year earlier, which included a $1.07 per share one-time tax benefit; adjusted EPS was $10.09 vs. $9.65.
Full-year 2025 adjusted EPS forecast raised to $42.10 to $42.60, from $41.25 to $42.00.
Estimated gross incremental tariff costs were cut to approximately $60 million annualized from $115 million, due to lower tariff rates.
Cousins Properties reported second quarter 2025 net income available to common stockholders of $14.5 million, or $0.09 per share, up from $7.8 million, or $0.05 per share, a year earlier. The company raised its full-year 2025 FFO guidance to $2.79 to $2.85 per share from $2.75 to $2.83, and it said it acquired The Link, a Dallas office property, for $218.0 million on July 28, 2025.
Q2 2025 FFO was $117.5 million, or $0.70 per share, compared with $103.3 million, or $0.68 per share, in Q2 2024
2025 net income guidance was raised to $0.28 to $0.34 per share from $0.26 to $0.34 per share
The Link, a 292,000 square foot office property in Uptown Dallas, was acquired on July 28 for $218.0 million
Company issued $500.0 million of 5.250% senior notes in Q2 and repaid $250.0 million of 3.91% private notes after quarter end
Mirion reported second-quarter 2025 revenue of $222.9 million, up 7.6% from a year earlier, and swung to GAAP net income of $8.5 million from a net loss of $12.0 million. The company raised its full-year 2025 guidance for total revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow and Adjusted EPS, while lowering its Organic Revenue growth range.
Q2 2025 revenue rose 7.6% to $222.9 million; GAAP net income was $8.5 million versus a $12.0 million loss in Q2 2024
Adjusted EBITDA was $51.2 million, up 4.9%; GAAP diluted EPS was $0.03 and Adjusted EPS was $0.11
2025 total revenue growth guidance raised to approximately 7.0%–9.0% from 5.0%–7.0%; Adjusted EBITDA guidance raised to $223 million–$233 million
Organic Revenue growth guidance revised down to approximately 5.0%–7.0% from 5.5%–7.5%, citing reductions in Labs & Research and Dosimetry Services
Bright Horizons reported second quarter 2025 revenue of $731.6 million, up 9%, and net income of $54.8 million, up 40%, with diluted EPS of $0.95 versus $0.67 a year earlier. The company also issued 2025 guidance of $2.9 billion to $2.92 billion in revenue and $4.15 to $4.25 in diluted adjusted EPS, but the filing does not compare that outlook with prior guidance.
Q2 2025 revenue $731.6 million, up 9% from $670.1 million; income from operations $86.1 million, up 25%
Q2 diluted EPS $0.95 versus $0.67; diluted adjusted EPS $1.07 versus $0.88
2025 outlook: revenue $2.9 billion to $2.92 billion; diluted adjusted EPS $4.15 to $4.25
Cash and equivalents $179.2 million at June 30, 2025; $483.3 million available under revolving credit facility
American Homes 4 Rent reported second quarter 2025 results, with rents and other single-family property revenues up 8.0% year-over-year to $457.5 million and net income attributable to common shareholders up to $105.6 million, or $0.28 per diluted share. The company raised its full-year 2025 Core FFO guidance midpoint by $0.03 per share to $1.86, which matters to shareholders because it signals stronger expected per-share operating results for the year.
Q2 2025 net income attributable to common shareholders was $105.6 million, or $0.28 per diluted share, versus $92.1 million, or $0.25, a year earlier.
Core FFO per share was $0.47 for Q2 2025, up 4.9% from $0.45 a year earlier.
Full-year 2025 Core FFO guidance rose to $1.84 to $1.88 from $1.80 to $1.86, citing stronger leasing and lower property tax expense outlook.
On June 30, 2025, the company had cash of $323.3 million and total outstanding debt of $5.2 billion.
Omega Healthcare Investors reported second-quarter 2025 net income of $140 million and adjusted funds from operations (AFFO) of $232 million, both up from a year earlier, and raised its full-year 2025 AFFO guidance to $3.04 to $3.07 per share from $2.95 to $3.01. The company also disclosed that tenant Genesis Healthcare filed for Chapter 11 bankruptcy on July 9, 2025, and said it expects to keep receiving full rent from Genesis during the process.
Q2 2025 AFFO was $232 million, or $0.77 per share, versus $185 million, or $0.71 per share, in Q2 2024.
Q2 2025 net income was $140 million, or $0.46 per share, versus $117 million, or $0.45 per share, a year earlier.
Full-year 2025 AFFO guidance was raised to $3.04 to $3.07 per diluted share from $2.95 to $3.01.
Genesis filed for Chapter 11 on July 9, 2025; Omega agreed to provide an $8.0 million debtor-in-possession financing.
Envista reported second-quarter 2025 sales of $682 million, up from $633 million a year earlier, and GAAP net income of $26 million, compared with a net loss of $1,152 million in the prior-year quarter that included a goodwill and intangible asset impairment. The company raised its full-year 2025 guidance, lifting core sales growth to 3% to 4% and adjusted diluted EPS to $1.05 to $1.15 from prior ranges of 1% to 3% and $0.95 to $1.05.
Q2 2025 sales were $682.1 million; core sales growth was 5.6%, and adjusted diluted EPS was $0.26, up from $0.11.
GAAP diluted EPS was $0.16 in Q2 2025, compared with a loss of $6.69 in Q2 2024.
Full-year 2025 adjusted diluted EPS guidance is $1.05 to $1.15, up from $0.95 to $1.05; core sales growth guidance is 3% to 4%, up from 1% to 3%.
During Q2 2025 the company repurchased 4.8 million shares for about $82 million and had $150 million remaining under its repurchase program.
SPX Technologies reported second-quarter 2025 revenue of $552.4 million, up 10.2%, and GAAP EPS of $1.10, up 14.6%, and raised its full-year 2025 guidance for revenue, adjusted EBITDA and adjusted EPS. For shareholders, the higher outlook reflects the company's view of demand and operations, while total debt rose to $1,019.3 million from $614.7 million at year-end 2024.
Q2 2025 revenue was $552.4 million, up 10.2%; GAAP income from continuing operations was $52.5 million, up 16.2%.
Full-year adjusted EBITDA guidance raised to $485 million to $510 million from $470 million to $495 million.
Full-year revenue guidance raised to $2.225 billion to $2.275 billion from $2.20 billion to $2.26 billion; adjusted EPS guidance raised to $6.35 to $6.65 from $6.10 to $6.40.
Total debt was $1,019.3 million at June 28, 2025, compared with $614.7 million at December 31, 2024.
Boot Barn reported first-quarter fiscal 2026 net sales of $504.1 million, up 19.1% from a year earlier, and net income of $53.4 million, or $1.74 per diluted share, compared with $1.26 a year earlier. The company raised its full-year fiscal 2026 outlook, now expecting net income per diluted share of $5.80 to $6.70, which matters to shareholders because it sets updated profit and sales expectations for the year.
Net sales rose 19.1% to $504.1 million; consolidated same store sales rose 9.4%.
Net income was $53.4 million, or $1.74 per diluted share, versus $38.9 million, or $1.26, a year earlier.
Full-year fiscal 2026 guidance: total sales of $2.100 billion to $2.180 billion and net income per diluted share of $5.80 to $6.70.
Second-quarter guidance calls for net income per diluted share of $1.19 to $1.27, with total sales of $487 million to $495 million.
Universal Display reported second quarter 2025 revenue of $171.8 million, up from $158.5 million a year earlier, and net income of $67.3 million, or $1.41 per diluted share, versus $1.10 in the prior-year quarter. The company raised the low end of its 2025 revenue guidance, which it now projects at $650 million to $700 million, and declared a third quarter dividend of $0.45 per share.
Q2 2025 total revenue $171.8 million vs. $158.5 million in Q2 2024; royalty and license fees rose to $75.7 million from $59.6 million
Material sales fell to $88.7 million from $95.4 million, which the company attributed to customer mix and lower unit material volume
Net income $67.3 million, or $1.41 per diluted share, vs. $52.3 million, or $1.10, a year earlier
2025 revenue guidance raised at the low end to $650 million to $700 million; $0.45 quarterly dividend payable September 30, 2025 to holders of record on September 16, 2025
AMETEK reported second-quarter 2025 net sales of $1.78 billion, up 2.5% from a year earlier, and GAAP diluted earnings of $1.55 per share versus $1.45. The company raised its full-year 2025 adjusted earnings guidance, citing the second-quarter results and its recently announced acquisition of FARO Technologies.
Q2 2025 net sales were $1.78 billion, up 2.5%; operating income rose 3% to $461.6 million.
Q2 GAAP diluted EPS was $1.55 versus $1.45; adjusted diluted EPS was $1.78, up 7% from $1.66.
2025 adjusted diluted EPS guidance is now $7.06 to $7.20, up from $7.02 to $7.18; overall sales are expected to rise mid-single digits.
Q3 2025 adjusted diluted EPS is expected at $1.72 to $1.76, and third-quarter sales are expected to rise mid-single digits.
EMCOR Group reported record second-quarter 2025 revenue of $4.30 billion, up 17.4%, and diluted EPS of $6.72, up 28.0%, with a record $11.91 billion in remaining performance obligations. The company raised its full-year 2025 non-GAAP diluted EPS guidance to $24.50-$25.75 from $22.65-$24.00 and narrowed its revenue guidance to $16.4 billion-$16.9 billion.
Q2 2025 revenue $4.30 billion, up 17.4% from $3.67 billion; net income $302.2 million, or $6.72 per diluted share
Operating margin 9.6% in Q2 2025 versus 9.1% a year earlier
Full-year 2025 non-GAAP diluted EPS guidance raised to $24.50-$25.75 from $22.65-$24.00; operating margin guidance raised to 9.0%-9.4%
Remaining performance obligations reached a record $11.91 billion as of June 30, 2025, up 32.4%
Schneider National reported second-quarter 2025 operating revenues of $1.4 billion, up 8% from a year earlier, and income from operations of $55.0 million, up 8%. Diluted earnings per share were flat at $0.20, and the company lowered the top end of its full-year 2025 adjusted diluted EPS guidance to $0.95 from $1.00, so shareholders see higher sales and operating profit alongside a narrower earnings outlook.
Operating revenues were $1,420.5 million for the three months ended June 30, 2025, compared with $1,316.7 million in 2024.
Income from operations was $55.0 million, compared with $51.0 million in the second quarter of 2024.
Diluted EPS was $0.20 in both periods; adjusted diluted EPS was $0.21 in both periods.
Full-year 2025 adjusted diluted EPS guidance is $0.75 to $0.95, down from the prior $0.75 to $1.00 range; net capital expenditure guidance of $325 to $375 million was unchanged.
IDACORP reported second quarter 2025 net income attributable to IDACORP of $95.8 million, or $1.76 per diluted share, up from $89.5 million, or $1.71 per diluted share, a year earlier. It raised the lower end of its full-year 2025 earnings guidance to $5.70 to $5.85 per diluted share from $5.65 to $5.85, with the upper end unchanged.
Q2 2025 net income was $95.8 million ($1.76 per diluted share) versus $89.5 million ($1.71) in Q2 2024.
Six-month 2025 earnings were $2.87 per diluted share, compared with $2.67 in the first six months of 2024.
2025 EPS guidance is now $5.70 to $5.85, assuming Idaho Power uses $60 million to $77 million of additional tax credits under the Idaho regulatory mechanism.
Higher retail revenues per MWh, customer growth, and usage were partly offset by higher depreciation and financing costs, according to the company.
APi Group reported second-quarter 2025 net revenue of $1.99 billion, up 15.0%, and reported net income of $77 million, up 11.6%. The company raised its full-year 2025 guidance for net revenue and adjusted EBITDA, and gave third-quarter guidance of $1.985 billion to $2.035 billion in net revenue, while gross margin fell 50 basis points.
Q2 2025 net revenue $1.99 billion, up 15.0% (8.3% organic); diluted EPS $0.16 versus $0.15 a year earlier
Adjusted EBITDA $272 million, up 17.7%; adjusted EBITDA margin rose 30 basis points to 13.7%
Full-year 2025 net revenue guidance raised to $7.65 billion to $7.85 billion, from $7.40 billion to $7.60 billion
Full-year adjusted EBITDA guidance raised to $1,005 million to $1,045 million, from $985 million to $1,035 million
Xylem reported second-quarter 2025 revenue of $2.3 billion, up 6% on both reported and organic bases, and earnings per share of $0.93, up 16%. The company raised its full-year 2025 revenue and adjusted earnings per share guidance, which matters to shareholders because both headline measures improved and the outlook was lifted.
Q2 2025 revenue was $2.3 billion, up 6% on reported and organic bases.
Q2 net income attributable to Xylem was $226 million, or $0.93 per share, up 16%; adjusted EPS was $1.26, also up 16%.
Full-year 2025 adjusted EPS guidance was raised to $4.70 to $4.85 from $4.50 to $4.70.
Full-year 2025 revenue is now forecast at about $8.9 to $9.0 billion, up about 4 to 5% on a reported basis, versus 1 to 2% previously.
Indivior PLC (Nasdaq: INDV) reported second-quarter 2025 results with total net revenue of $302 million, up 1% from a year earlier, and net income of $18 million, compared with a net loss of $97 million in Q2 2024. The company raised its full-year 2025 net revenue guidance to $1,030 million to $1,080 million and its adjusted EBITDA guidance to $275 million to $300 million, but Q2 adjusted EBITDA fell to $88 million from $93 million as marketing spending increased.
Q2 2025 total net revenue of $302 million, up 1% from $299 million in Q2 2024; U.S. SUBLOCADE net revenue rose 9% to $195 million
Q2 2025 net income of $18 million and diluted EPS of $0.14, versus a net loss of $97 million and diluted loss of $0.72 per share a year earlier
FY 2025 net revenue guidance raised to $1,030 million to $1,080 million from $955 million to $1,025 million; adjusted EBITDA guidance raised to $275 million to $300 million from $220 million to $260 million
Q2 2025 adjusted EBITDA of $88 million, down from $93 million, mainly reflecting increased marketing for U.S. SUBLOCADE
Kimco Realty reported second-quarter 2025 net income available to common shareholders of $155.4 million, or $0.23 per diluted share, up from $0.17 a year earlier, and raised its 2025 net income and FFO per share outlook. FFO per diluted share rose 7.3% to $0.44, supporting the higher full-year guidance for shareholders.
Q2 2025 net income per diluted share was $0.23 vs. $0.17 in Q2 2024; FFO per diluted share was $0.44, up 7.3%.
2025 FFO per diluted share outlook raised to $1.73 to $1.75 from $1.71 to $1.74; net income outlook raised to $0.74 to $0.76 from $0.70 to $0.73.
Same property NOI rose 3.1% in the quarter; small shop occupancy reached a record 92.2%.
Quarterly common dividend of $0.25 per share declared, payable September 19, 2025, to holders of record September 5, 2025.
Vontier reported second-quarter 2025 sales of $773.5 million, up 11.1% from a year earlier, and adjusted diluted EPS of $0.79 versus $0.63 a year earlier. The company raised its full-year 2025 adjusted diluted EPS guidance to $3.10 to $3.20 and gave Q3 2025 adjusted EPS guidance of $0.74 to $0.78, which gives shareholders a higher profit outlook for the year.
Q2 2025 sales were $773.5 million, up 11.1%; core sales rose 10.8%
GAAP diluted EPS was $0.62 versus $0.45 a year earlier; adjusted diluted EPS was $0.79 versus $0.63
Full-year 2025 adjusted diluted EPS guidance raised to $3.10 to $3.20; Q3 2025 guidance is $0.74 to $0.78
Repurchased about 1.4 million shares for about $50 million in Q2; $105 million year to date
ITT reported second-quarter 2025 revenue of $972.4 million, up 7.3% from a year earlier, and diluted EPS of $1.52, up 4.8%. The company raised its full-year 2025 revenue and EPS guidance, citing year-to-date performance and a more stable demand outlook for the second half.
Q2 revenue of $972.4 million rose 7.3% (4.3% organic) versus the prior year quarter.
Q2 diluted EPS was $1.52, up 4.8%; adjusted EPS was $1.64, up 10.1%.
2025 guidance: revenue growth of 5% to 7%, EPS of $5.95 to $6.15, and adjusted EPS of $6.35 to $6.55.
Quarterly dividend of $0.351 per share is payable September 29, 2025 to holders of record on September 2, 2025.
Omnicell reported second quarter 2025 total revenues of $291 million, up 5% from a year earlier, and GAAP net income of $6 million, or $0.12 per diluted share. Non-GAAP net income fell to $21 million, or $0.45 per share, from $24 million, or $0.51, a year earlier. The company raised its full-year 2025 total revenue, non-GAAP EBITDA and non-GAAP EPS guidance, while reaffirming its product bookings and annual recurring revenue outlook.
Q2 2025 total revenues were $291 million, up $14 million, or 5%, from Q2 2024
GAAP net income was $6 million ($0.12 per diluted share), versus $4 million ($0.08) a year earlier; non-GAAP net income was $21 million ($0.45), versus $24 million ($0.51)
Full-year 2025 total revenue guidance is now $1.130 billion to $1.160 billion; non-GAAP EBITDA guidance is $130 million to $145 million; non-GAAP EPS guidance is $1.40 to $1.65
Operating cash flow was $43 million in Q2 2025, down from $59 million in Q2 2024
Biogen reported second quarter 2025 revenue of $2.6 billion, up 7% from a year earlier, with GAAP diluted EPS of $4.33, up 8%, and non-GAAP diluted EPS of $5.47, up 4%. The company raised its full-year 2025 non-GAAP diluted EPS guidance to $15.50-$16.00 from $14.50-$15.50, and its revenue outlook to roughly flat at constant currency from a mid-single-digit decline, which points to higher expected earnings for shareholders.
Q2 2025 total revenue was $2,646 million, up 7% year over year; GAAP diluted EPS was $4.33 and non-GAAP diluted EPS was $5.47.
Full-year 2025 non-GAAP diluted EPS guidance was raised to $15.50-$16.00 from $14.50-$15.50, including a $0.87 benefit from a stronger outlook partly offset by a ~$0.12 impact from the City Therapeutics transaction.
Q2 results included about $47 million of acquired IPR&D, upfront and milestone expense, an approximately $0.26 per-share impact.
Biogen expects minimal contract manufacturing revenue in Q4 2025 due to planned plant maintenance and expects increased competitive pressure on ex-U.S. MS sales in the second half.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.